Navigation Links
Chicago-Based Celsis International Goes Private
Date:10/9/2009

CHICAGO, Oct. 9 /PRNewswire/ -- Chicago-based Celsis International, a leading global life sciences company, announces today that it has completed its public-to-private transaction process and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.

"Celsis has a very strong track record of consistent revenue and mid-teens profit growth, yet our strong financial results were not being reflected in our share price," explains Jay LeCoque, CEO of Celsis. "It is important to our future--both to our large customer base and to our employees here in Chicago and around the world--that we are able to continue to invest in and grow the business. Going private allows us the ability to focus more on our long term strategic growth opportunities." Celsis has been acquired by UK-based private equity firm JO Hambro, which has retained Mr. LeCoque and Christian Madrolle, Celsis' CFO, in their current management and Board positions.

Founded by serial entrepreneur Sir Christopher Evans, Celsis was floated on the LSE in 1993 and was a member of the techMARK Mediscience index. Named best performing share in 2003, the company consistently posted mid-teens profit growth numbers and has been profitable since 2001.

Celsis products and services deliver substantial time and cost savings to major pharmaceutical and consumer product companies while ensuring product quality and safety for consumers. Its customers include all of the top 25 pharma companies and Fortune 50 consumer product companies. Celsis employs 40 people in Chicago and another 200 worldwide. Its divisions include: Celsis Rapid Detection, the world leader in rapid microbial testing for industry; Celsis Analytical Services, providing cost effective analytical laboratory testing services to pharmaceutical and consumer product manufacturers; and Celsis In Vitro Technologies, a pioneer and leader of in vitro ADME-Tox products used to reduce the cost of drug discovery and development.

More information is online at celsis.com.

SOURCE Celsis International


'/>"/>
SOURCE Celsis International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Celsis Receives Frost & Sullivan 2008 Best Practices Award
2. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
3. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
4. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
5. Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
8. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
9. Arrow International Files and Mails Definitive Proxy Materials
10. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
11. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):